171. ウィルソン病 Wilson disease Clinical trials / Disease details
臨床試験数 : 68 / 薬物数 : 79 - (DrugBank : 17) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 28
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1900023410 | 2019-06-01 | 2019-05-26 | The application of quantitative susceptibility mapping and blood and urine cell culture in Wilson's disease | The application of quantitative susceptibility mapping and blood and urine cell culture in Wilson's disease | Wilson’s disease | Gold Standard:The main clinical diagnostic criteria: 1) liver disease history, liver disease symptoms or extravertebral system symptoms; 2) serum ceruloplasmin was significantly decreased and/or liver copper increased; 3) corneal Kayser-Fleischer ring; 4) positive family history.;Index test:Quantitative susceptibility mapping; | Shanghai Tongren Hospital | NULL | Recruiting | Both | Target condition:40;Difficult condition:20 | China | |||
| 2 | ChiCTR-DDD-17010552 | 2017-01-25 | 2017-02-04 | Genetic diagnosis of Wilson's disease | Genetic diagnosis of Wilson's disease | Wilson Disease | Gold Standard:Clinical symptoms; Family history of genetic; Plasma ceruloplasmin levels;Urine copper levels of 24 hours; The nervous system of assessment and head imaging examination;Index test:Determination of gene sequence of the gene of ATP7B; | Anhui Provincial Hospital | NULL | Recruiting | Both | Target condition:20;Difficult condition:0 | China |